RedHill Biopharma up as bacterial infection drug gets EU 'orphan' tag

Redhill Biopharma

17/08/2022 14:15

** U.S.-listed shares of RedHill Biopharma Ltd  RDHL.O  rise
4.1% to $1.02 premarket
    ** RDHL says the European Commission has granted "orphan"
drug designation to RHB-204, its experimental treatment for 
nontuberculous mycobacteria (NTM) disease  urn:newsml:reuters.com:*:nPnPvbDha
    ** NTMs are bacteria that can be found in soil, dust and
water and can cause infections in several body sites, with lungs
being most commonly affected
    ** RDHL is currently conducting a late-stage study in the
U.S. to evaluate the efficacy and safety of RHB-204 in adults
with lung disease caused by NTM
    ** Stock down 62% YTD, as of last close

 (Reporting by Amruta Khandekar)
 ((Amruta.Khandekar@thomsonreuters.com;))